皮科拼图:公共数据能否预测欧盟对所有欧盟国家的HTA期望?
Karolin Eberle1, Lisa-Maria Hagemann1, Maria Katharina Schweitzer1
1AMS Advanced Medical Services GmbH, 80639 Munich, Germany; karolin.eberle@ams-europe.com (K.E.); lisa-maria.hagemann@ams-europe.com (L.-M.H.); maria.schweitzer@ams-europe.com (M.K.S.); martin.justl@ams-europe.com (M.J.); jana.maurer@ams-europe.com (J.M.); alexandra.carls@ams-europe.com (A.C.).
Journal of market access & health policy
|July 25, 2025
概括
医疗技术开发人员可以使用公共数据可靠地预测联合临床评估 (JCA) PICO元素. 预测比较对象是欧盟HTA法规下瘤学和先进疗法药品档案的关键.
科学领域:
- 卫生经济学和结果研究 (HEOR)
- 监管科学 监管科学
- 制药政策 制药政策
背景情况:
- 欧盟 (欧盟) 卫生技术评估 (HTA) 条例要求对特定药品进行联合临床评估 (JCA).
- PICO框架 (人口,干预,比较,结果) 定义了JCA的范围,这对于在紧张的时间表下准备档案至关重要.
- 医疗技术开发人员 (HTD) 需要提前预测PICO元素,以便有效开发档案.
研究的目的:
- 通过公开可用的信息,调查欧盟成员国中JCA的PICO元素的可预测性.
- 评估公共数据的可用性,以预测HTA提交的PICO要求.
主要方法:
- 系统的文献审查以确定相关的同行评审文章.
- 在29个欧洲国家广泛搜索公开的HTA文件 (报告,指导方针,模板,市场准入信息).
- 提取与PICO元素相关的相关信息以进行预测.
主要成果:
- 与HTA相关的信息具有显著的公众可访问性:66%的HTA报告,79%的方法指南,69%的档案模板和100%的市场准入清单.
- 人口和结果要求在各国之间显示一致,突出显示比较器是PICO预测的中心元素.
- 基于公开可访问的信息,可以可靠地预测PICO元素.
结论:
- 公开可用的数据为预测联合临床评估中的PICO元素提供了可靠的基础.
- 医疗技术开发商应该利用这些信息来准备战略文件,同时保持适应不断变化的国家程序的能力.
- 积极预测PICO,特别是比较器,对于有效地导航欧盟HTA领域至关重要.
相关概念视频
Hazard Ratio
251
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
251
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
176
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
176
Regression Toward the Mean
6.5K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.5K
Drug Control Governance: Regulatory Bodies and Their Impact
250
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
250
Analysis of Population Pharmacokinetic Data
387
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
387
Pharmacovigilance
996
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
996


